A study published in the latest edition of JACC: Cardiovascular Imaging suggests cardiac magnetic resonance imaging can be as effective as measurements of fractional flow reserve in evaluating nonculprit lesions after STEMI.

Amarin on Jan. 13 announced the launch of True to Your Heart, a new educational campaign geared toward heart patients who remain at a persistent risk for CVD despite being treated with statins and other standard-of-care therapies.

An analysis of 12 recent randomized clinical trials suggests a majority of patients with ischemic heart disease or a history of MI are eligible for new secondary prevention therapies—a finding that, if acted upon, could change a paradigm that’s been in place for decades.

Research out of Norway suggests obesity, high blood pressure and diabetes could have a lot to do with CVD’s tendency to present later in life in women than in men.

A study published in JAMA Cardiology Jan. 2 suggests physicians may achieve comparable results when using either radial or femoral access for primary PCI in patients with STEMI.

Updated screening technologies and more widespread use of statins have rendered aspirin ineffective for the primary prevention of CVD, according to a study published in Family Practice.

A study published in JACC suggests that, when combined with high-intensity statin therapy, evolocumab can be an effective tool for lowering LDL-cholesterol in patients who have experienced an acute coronary syndrome.

Surgical candidates with active cannabis use disorders were nearly twice as likely as their non-user peers to suffer a heart attack after surgery, according to research published in Anesthesiology on Nov. 25.

A cardiologist in Madrid, Spain, thinks physicians could leverage data from later-generation Apple Watches to diagnose heart attacks, HealthDay News reported Nov. 25.

More than 10% of cancer patients in the U.S. die not from their cancer but from cardiovascular complications, according to a study published in the European Heart Journal Nov. 25.

A study published in the November issue of the Journal of the American College of Cardiology confirms that patients defined as “very high risk” for future ASCVD events by updated society guidelines do indeed carry a much higher risk of adverse outcomes down the road.

A group of researchers in the U.K. reported this week that even slight increases in a person’s cardiac troponin levels predict adverse outcomes—including early death—in patients of all ages.